ストックスクリーナーアプリを入手
9.675
6.55%
0.595
アフターアワーズ：
9.68
0.005
+0.05%
前日終値:
$9.08
開ける：
$9.31
24時間の取引高:
52,747
Relative Volume:
0.50
時価総額：
$180.95M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-8.38%
1か月 パフォーマンス:
+15.87%
6か月 パフォーマンス:
+109.42%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$8.8501
$9.75
1週間の範囲:
$8.85
$10.69
52週間の値動き範囲:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
名前
Kalaris Therapeutics Inc
セクター
電話
650-249-2727
住所
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
9.675 | 169.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-11-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-07-23 | 再開されました | Piper Sandler | Neutral |
| 2025-05-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-08 | 開始されました | William Blair | Outperform |
すべてを表示
Kalaris Therapeutics Inc (KLRS) 最新ニュース
KLRS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kalaris Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
KLRS Should I Buy - Intellectia AI
Published on: 2026-02-28 06:52:09 - baoquankhu1.vn
ETFs Investing in Kalaris Therapeutics, Inc. Stocks - TradingView
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold - MarketBeat
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therape - GuruFocus
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therapeutics Inc - GuruFocus
Sell Signal: Is CRISPR Therapeutics AG backed by strong institutional buyingGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Kalaris Therapeutics Insider Bought Shares Worth $5,000,006, According to a Recent SEC Filing - marketscreener.com
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock - MarketBeat
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares By Investing.com - Investing.com South Africa
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares - Investing.com Australia
Akkaraju group reports 56.5% Kalaris (KLRS) ownership stake - Stock Titan
RTW discloses 5.7% Kalaris Therapeutics (KLRS) ownership stake - Stock Titan
Earnings Miss: How Kalaris Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Action & Weekly Market Pulse Alerts - mfd.ru
Is Kalaris Therapeutics Inc. undervalued by DCF analysisSwing Trade & Capital Efficiency Focused Ideas - mfd.ru
Will Kalaris Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Fast Gain Stock Tips - mfd.ru
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Kalaris Therapeutics Inc. stock is trending among retail tradersQuarterly Investment Review & High Return Trade Opportunity Guides - mfd.ru
Kalaris Therapeutics Emerges with Focused Retinal Disease Strategy - AD HOC NEWS
Institution Moves: Whats the profit margin of Kalaris Therapeutics IncTrade Exit Report & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8% - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Smart Money: Should I add Kalaris Therapeutics Inc stock to my portfolioJuly 2025 Big Picture & Real-Time Buy Signal Notifications - baoquankhu1.vn
Kalaris to present phase 1 data of novel eye therapy at Macula Society - Investing.com Australia
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting - Investing News Network
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Kalaris Therapeutics raises $50M privately - MSN
What’s the MACD signal for Kalaris Therapeutics Inc.Double Top/Bottom Patterns & High Return Capital Strategies - bollywoodhelpline.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Buyback Watch: Will Kalaris Therapeutics Inc outperform small cap indexesJuly 2025 Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Block Trades: Can Kalaris Therapeutics Inc weather a recessionWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Swing Trade: Is Kalaris Therapeutics Inc. affected by consumer sentimentInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Support Test: What is Kalaris Therapeutics Incs 5 year growth outlookRecession Risk & AI Powered Market Entry Ideas - baoquankhu1.vn
How Kalaris Therapeutics Inc. stock responds to policy changesMarket Sentiment Report & Technical Pattern Based Buy Signals - Улправда
Why retail investors pile into Kalaris Therapeutics Inc. stockJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Is Kalaris Therapeutics Inc. stock a defensive play in 2025Treasury Yields & Reliable Volume Spike Trade Alerts - Улправда
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Kalaris Therapeutics Inc (KLRS) 財務データ
Kalaris Therapeutics Inc (KLRS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.69%
0.71%
大文字化:
|
ボリューム (24 時間):